The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease

Journal of Neuroimmunology

Volumn 283, Issue , 2015, Pages 50-57

  Dursun, Erdinç ^a   Gezen Ak, Duygu ^a   Hanağasi, Haşmet ^b   Bilgiç, Başar ^b   Lohmann, Ebba ^b   Ertan, Sibel ^a   Atasoy, Irem L ^a   Alaylioğlu, Merve ^a   Araz, Ömür Selin ^a   Önal, Burak ^a   Gündüz, Ayşegül ^a   Apaydin, Hülya ^a   Kiziltan, Güneş ^a   Ulutin, Turgut ^a   Gürvit, Hakan ^b   Yilmazer, Selma ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Alpha 2 macroglobulin ( 2 macroglobulin); Alzheimer's disease; Biomarker; Brain derived neurotrophic factor (BDNF); Heat shock protein 90 (Hsp90); Interleukin 1 alpha (IL 1 ); Interleukin 1 beta (IL 1 ); Interleukin 10 (IL 10); Interleukin 6 (IL 6); Mild cognitive impairment (MCI); Parkinson's disease (PD); Tumor necrosis factor alpha (TNF )

Indexed keywords

ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; COMPLEMENT FACTOR H; HEAT SHOCK PROTEIN 90; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; IL6 PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EARLY ONSET ALZHEIMER DISEASE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; MULTIPLE REGRESSION; NERVOUS SYSTEM INFLAMMATION; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; COMPARATIVE STUDY; FEMALE; IMMUNOLOGY; INFLAMMATION; MALE; MIDDLE AGED; VERY ELDERLY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALPHA-MACROGLOBULINS; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE;

EID: 84929601144     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.04.014     Document Type: Article

References (50)

1. Alvarez X.A., Franco A., Fernandez-Novoa L., Cacabelos R. Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol. Chem. Neuropathol. 1996, 29:237-252.
2. Angelis P., Scharf S., Mander A., Vajda F., Christophidis N. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. Neurosci. Lett. 1998, 244:106-108.
3. Angelopoulos P., Agouridaki H., Vaiopoulos H., Siskou E., Doutsou K., Costa V., et al. Cytokines in Alzheimer's disease and vascular dementia. Int. J. Neurosci. 2008, 118:1659-1672.
4. Bermejo P., Martin-Aragon S., Benedi J., Susin C., Felici E., Gil P., et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol. Lett. 2008, 117:198-202.
5. Bjorkqvist M., Ohlsson M., Minthon L., Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One 2012, 7:e29868.
6. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 1995, 202:17-20.
7. Brodacki B., Staszewski J., Toczylowska B., Kozlowska E., Drela N., Chalimoniuk M., et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci. Lett. 2008, 441:158-162.
8. Brosseron F., Krauthausen M., Kummer M., Heneka M.T. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol. Neurobiol. 2014, 50(2):534-544.
9. Choi C., Jeong J.H., Jang J.S., Choi K., Lee J., Kwon J., et al. Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer's disease by color-coded bead technology. J. Clin. Neurol. 2008, 4:84-88.
10. Cojocaru I.M., Cojocaru M., Miu G., Sapira V. Study of interleukin-6 production in Alzheimer's disease. Rom. J. Intern. Med. 2011, 49:55-58.
11. Corsi M.M., Licastro F., Porcellini E., Dogliotti G., Galliera E., Lamont J.L., et al. Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration. Biogerontology 2011, 12:451-454.
12. Cutler P., Akuffo E.L., Bodnar W.M., Briggs D.M., Davis J.B., Debouck C.M., et al. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin. Appl. 2008, 2:467-477.
13. De Luigi A., Fragiacomo C., Lucca U., Quadri P., Tettamanti M., Grazia De Simoni M. Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech. Ageing Dev. 2001, 122:1985-1995.
14. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
15. Dufek M., Hamanova M., Lokaj J., Goldemund D., Rektorova I., Michalkova Z., et al. Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:318-320.
16. Forlenza O.V., Diniz B.S., Talib L.L., Mendonca V.A., Ojopi E.B., Gattaz W.F., et al. Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 2009, 28:507-512.
17. Gadient R.A., Otten U.H. Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog. Neurobiol. 1997, 52:379-390.
18. Gezen-Ak D., Dursun E., Hanagasi H., Bilgic B., Lohman E., Araz O.S., et al. BDNF, TNFalpha, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer's disease or mild cognitive impairment. J. Alzheimers Dis. 2013, 37:185-195.
19. Helmy A.A., Naseer M.M., Shafie S.E., Nada M.A. Role of interleukin 6 and alpha-globulins in differentiating Alzheimer and vascular dementias. Neurodegener. Dis. 2012, 9:81-86.
20. Hofmann K.W., Schuh A.F., Saute J., Townsend R., Fricke D., Leke R., et al. Interleukin-6 serum levels in patients with Parkinson's disease. Neurochem. Res. 2009, 34:1401-1404.
21. Kalman J., Juhasz A., Laird G., Dickens P., Jardanhazy T., Rimanoczy A., et al. Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease. Acta Neurol. Scand. 1997, 96:236-240.
22. Khemka V.K., Ganguly A., Bagchi D., Ghosh A., Bir A., Biswas A., et al. Raised serum proinflammatory cytokines in Alzheimer's disease with depression. Aging Dis. 2014, 5:170-176.
23. Koziorowski D., Tomasiuk R., Szlufik S., Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine 2012, 60:762-766.
24. Lanzrein A.S., Johnston C.M., Perry V.H., Jobst K.A., King E.M., Smith A.D. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis. Assoc. Disord. 1998, 12:215-227.
25. Lee K.S., Chung J.H., Lee K.H., Shin M.J., Oh B.H., Hong C.H. Bioplex analysis of plasma cytokines in Alzheimer's disease and mild cognitive impairment. Immunol. Lett. 2008, 121:105-109.
26. Licastro F., Parnetti L., Morini M.C., Davis L.J., Cucinotta D., Gaiti A., et al. Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1995, 9:112-118.
27. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C., et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?. J. Neuroimmunol. 2000, 103:97-102.
28. Lindqvist D., Kaufman E., Brundin L., Hall S., Surova Y., Hansson O. Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. PLoS One 2012, 7:e47387.
29. Marksteiner J., Kemmler G., Weiss E.M., Knaus G., Ullrich C., Mechtcheriakov S., et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 2011, 32:539-540.
30. Marksteiner J., Imarhiagbe D., Defrancesco M., Deisenhammer E.A., Kemmler G., Humpel C. Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study. Exp. Gerontol. 2014, 50:114-121.
31. McGeer P.L., McGeer E.G. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 2001, 22:799-809.
32. Muller T., Blum-Degen D., Przuntek H., Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol. Scand. 1998, 98:142-144.
33. Ozturk C., Ozge A., Yalin O.O., Yilmaz I.A., Delialioglu N., Yildiz C., et al. The diagnostic role of serum inflammatory and soluble proteins on dementia subtypes: correlation with cognitive and functional decline. Behav. Neurol. 2007, 18:207-215.
34. Petersen A.M., Pedersen B.K. The role of IL-6 in mediating the anti-inflammatory effects of exercise. J. Physiol. Pharmacol. 2006, 57(Suppl. 10):43-51.
35. Pirttila T., Mehta P.D., Frey H., Wisniewski H.M. Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. Neurobiol. Aging 1994, 15:313-317.
36. Rao J.S., Kellom M., Kim H.W., Rapoport S.I., Reese E.A. Neuroinflammation and synaptic loss. Neurochem. Res. 2012, 37:903-910.
37. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 2007, 13:1359-1362.
38. Rehman A.A., Ahsan H., Khan F.H. Alpha-2-macroglobulin: a physiological guardian. J. Cell. Physiol. 2013, 228:1665-1675.
39. Richartz E., Stransky E., Batra A., Simon P., Lewczuk P., Buchkremer G., et al. Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease?. J. Psychiatr. Res. 2005, 39:535-543.
40. Ringheim G.E., Burgher K.L., Heroux J.A. Interleukin-6 mRNA expression by cortical neurons in culture: evidence for neuronal sources of interleukin-6 production in the brain. J. Neuroimmunol. 1995, 63:113-123.
41. Roberts R.C. Alpha-2-macroglobulin. J. Med. 1985, 16:129-224.
42. Scalzo P., Kummer A., Cardoso F., Teixeira A.L. Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci. Lett. 2010, 468:56-58.
43. Tarkowski E., Blennow K., Wallin A., Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J. Clin. Immunol. 1999, 19:223-230.
44. Tong L., Prieto G.A., Kramar E.A., Smith E.D., Cribbs D.H., Lynch G., et al. Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1beta via p38 mitogen-activated protein kinase. J. Neurosci. 2012, 32:17714-17724.
45. Weber A., Wasiliew P., Kracht M. Interleukin-1 (IL-1) pathway. Sci. Signal. 2010, 3:cm1.
46. Wetterling T., Tegtmeyer K.F. Serum alpha(1)-antitrypsin and alpha(2)-macroglobulin in Alzheimer's and Binswanger's-disease. Clin. Investig. 1994, 72:196-199.
47. Wolf B.B., Gonias S.L. Neurotrophin binding to human alpha 2-macroglobulin under apparent equilibrium conditions. Biochemistry 1994, 33:11270-11277.
48. Yasutake C., Kuroda K., Yanagawa T., Okamura T., Yoneda H. Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur. Arch. Psychiatry Clin. Neurosci. 2006, 256:402-406.
49. Zuliani G., Guerra G., Ranzini M., Rossi L., Munari M.R., Zurlo A., et al. High interleukin-6 plasma levels are associated with functional impairment in older patients with vascular dementia. Int. J. Geriatr. Psychiatry 2007, 22:305-311.
50. Zuliani G., Cavalieri M., Galvani M., Passaro A., Munari M.R., Bosi C., et al. Markers of endothelial dysfunction in older subjects with late onset Alzheimer's disease or vascular dementia. J. Neurol. Sci. 2008, 272:164-170.